vimarsana.com

Page 5 - நாட்கோ பார்மா வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NATCO receives approval for Chlorantraniliprole (CTPR)-1st key product of Crop Health Sciences Division

Natco launches anticoagulant tablet Rivaroxaban in India

Natco launches anticoagulant tablet Rivaroxaban in India Natco launches anticoagulant tablet Rivaroxaban in India 18 December 2020 | News Source credit: Shutterstock Natco Pharma Limited has announced the launch of Rivaroxaban molecule, under brand RPIGAT. Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots. Rivaroxaban is currently sold by Bayer under brand name of Xarelto®, in the Indian market. After successful previous launches of DABIGAT (Dabigatran) and AP IGAT (Apixaban) by NATCO, this latest Rivaroxaban NOAC (Novel oral anti-coagulant) is in line with the Company’s mission of affordable medicines accessible to all. NATCO has launched RPIGAT in four strengths- 20 mg, 15 mg, 10 mg and 2.5 mg. The 20 mg strength is priced at an MRP of Rs 14.0 per tablet.

NATCO launches anti blood clot tablet Rivaroxaban in India

NATCO launches anti blood clot tablet Rivaroxaban in India
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.